New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...
A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
specificity and accuracy for the detection of early-stage lung cancer. CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of ...
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a ...
The firm's artificial intelligence-based biomarker tools including Lunit Scope IO and Lunit Scope Universal IHC will be available across trials at the Center for Cancer Research.
MedPage Today on MSN2d
Lung Cancer Screening Rates Nearly 4 Times Lower Than Breast, Colon CancersPopulation-weighted estimates showed that fewer than 18% of eligible patients actually got a low-dose CT scan for lung cancer ...
Lung cancer screening with low-dose CT could have saved tens of thousands of lives — if only we'd listened to the data back ...
Precious metals are not merely ornaments; they are also important components of pharmaceuticals, like the antitumor drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback